Ischemic Mitral Regurgitation: Long-Term Outcome and Prognostic Implications With Quantitative Doppler Assessment

By F. Grigioni, M. Enriquez-Sarano, K. Zehr, Kent R. Bailey, A. Tajik. Circulation, 2001

1,449 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/2d6ed82ed6441ca2d59fe2c8e98925c85977f270

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

R. Hahn
R. Lang
W. Zoghbi
D. Adams
P. Thavendiranathan
E. Foster
A. Vahanian
P. Grayburn

Citations in the corpus

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. (2017, background): “One is obligated to describe the mechanism and possible etiologies, particularly in clinically significant regurgitation, as these affect the severity of regurgitation, cardiac remodeling, and management.(7,10,11) The mechanism of regurgitation is not necessarily synonymous with the cause.”
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). (2012, unknown): “2 Natural history Patients with chronic ischaemic MR have a poor prognosis.(118,142) The presence of severe CAD and LV dysfunction have prognostic importance.”
[2017 ESC/EACTS Guidelines for the management of valvular heart disease]. (2017, background): “The presence of chronic secondary mitral regurgitation is associated with impaired prognosis.(135) However, in contrast to primary mitral regurgitation, there is currently no evidence that a reduction of secondary mitral regurgitation improves survival.”
Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (2006, background): “for EROA and 30 ml for regurgitant volume: Table 5) [17, 118, 142].”